For example, in a murine model of lung adenocarcinoma, Koyoma et al. demonstrated that TIM-3 was upregulated after PD-1 blockade therapy, and that targeting TIM-3, following a PD-1 blockade failure, offered a survival advantage [223]. The gene discussed is HAVCR2; the disease is lung adenocarcinoma.